The rationale of inhibiting the complement system for therapeutic combinations to enhance the anti-tumor efficacy of anti-PD-1/PD-L1 checkpoint inhibitors has been proposed based on the supporting evidence that complement blocks many of the effector routes associated with the cancer-immunity cycle39. This evidence concerns the gene CD274 and neoplasm.